BE Therapeutics

📍 New York City Metropolitan Area, United States🗓 Founded 2023👥 5 employees💰 Last funded Apr 2025
Biotechnology Research
LinkedIn
What if we could restore brain function for the tens of millions of individuals who suffer from permanent brain damage? Strokes, traumas, neurodegeneration, and tumors can all cause permanent brain damage, but as of now there are no treatments that enable affected individuals to regain lost abilities. Consequently, they remain dependent on costly care for the rest of their lives. The aim of the Brain Repair program is to develop methods for replacing damaged brain tissue, enabling patients to regain lost function. The success of BE Therapeutics will bring relief to the millions of people world-wide suffering from permanent brain damage.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2023
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
1
Frequently asked questions
Who invested in BE Therapeutics?
BE Therapeutics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did BE Therapeutics last raise funding?
The most recent investment in BE Therapeutics recorded on gritt.io was in April 2025.
When was BE Therapeutics founded?
BE Therapeutics was founded in 2023.
What industry is BE Therapeutics in?
BE Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is BE Therapeutics based?
BE Therapeutics is headquartered in New York City Metropolitan Area, United States.